Receptor-mediated Modulation of Human Monocyte, Neutrophil, Lymphocyte, and Platelet Function by Phorbol Diesters
Open Access
- 1 October 1982
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 70 (4) , 699-706
- https://doi.org/10.1172/jci110665
Abstract
The tumor promoting phorbol diesters elicit a variety of responses from normal and leukemic blood cells in vitro by apparently interacting with cellular receptors. The biologically active ligand [20-3H] phorbol 12,13-dibutyrate ([3H]PDBu) bound specifically to intact human lymphocytes, monocytes, polymorphonuclear leukocytes (PMN), and platelets, but not to erythrocytes. Binding, which was comparable for all four blood cell types, occurred rapidly at 23° and 37°C, reaching a maximum by 20-30 min usually followed by a 30-40% decrease in cell associated radioactivity over the next 30-60 min. The time course for binding was temperature dependent with equilibrium binding occurring after 120-150 min at 4°C, with no subsequent loss of cell-associated radioactivity at this temperature. Bound [3H]PDBu could be eluted by addition of unlabeled PDBu. Scatchard analysis of data from 4°C binding studies revealed linear plots with high affinity receptors in these cell types with dissociation constants and receptors per cell of 60 nM and 7.8 × 105/cell for lymphocytes, 51 nM and 15.5 × 105/cell for monocytes, 38 nM and 4.0 × 105/cell for PMN, and 19 nM and 2.9 × 104/cell for platelets. Structure-activity studies using unlabeled phorbol-related compounds demonstrated a close correlation between their abilities to inhibit binding of [3H]PDBu to cells and their abilities to induce cellular responses (monocyte and PMN H2O2 secretion, lymphocyte 3HTdR incorporation, and platelet tritiated serotonin release); phorbol and 4-alpha phorbol were inactive while phorbol 12-myristate 13-acetate (PMA), PDBu, mezerein, and phorbol 12,13-diacetate (in decreasing order of potency) inhibited [3H]PDBu binding and elicited the various responses. Thus, these high affinity, specific receptors for the phorbol diesters, present on monocytes, lymphocytes, PMN, and platelets, mediate the pleiotypic effects induced by these ligands.This publication has 33 references indexed in Scilit:
- Phorbol diester-induced macrophage differentiation of leukemic blasts from patients with human myelogenous leukemia.Journal of Clinical Investigation, 1980
- Characterization of specific binding of [3H]phorbol 12,13-dibutyrate and [3H]phorbol 12-myristate 13-acetate to mouse brain.1980
- Specific binding of phorbol ester tumor promoters to mouse skinCell, 1980
- DIFFERENTIATION OF HUMAN LEUKEMIAS IN RESPONSE TO 12-0-TETRADECANOYLPHORBOL-13-ACETATE INVITRO1980
- ACTIVITY OF PHORBOL ESTER TUMOR PROMOTERS ON ENUCLEATED SWISS 3T3 CELLS1980
- Specific binding of phorbol ester tumor promotersProceedings of the National Academy of Sciences, 1980
- In vitro studies on the mode of action of the phorbol esters, potent tumor promoters: Part 1CRC Critical Reviews in Toxicology, 1980
- Receptor-mediated uptake and degradation of 125I-chemotactic peptide by human neutrophils.Journal of Biological Chemistry, 1979
- Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester.Proceedings of the National Academy of Sciences, 1979
- Lymphocyte Activation by the Tumor-Promoting Agent 12-O-Tetradecanoylphorbol-13-Acetate (TPA)The Journal of Immunology, 1979